This page shows the latest Kite news and features for those working in and with pharma, biotech and healthcare.
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.
Following the acquisition, BioNTech will also extend its cell therapy pipeline using the TCR platform from Kite. ... Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta
Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL). ... As the leader in cell therapy, Kite is honoured to deliver this landmark study and
Kite – a Gilead company – has entered into a strategic partnership with Shoreline Biosciences to develop novel allogeneic cell therapies across a range of cancer targets. ... Earlier this year, Kite signed a research collaboration agreement with
First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent ... Kite also recently revealed some positive data for
Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis. ... Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL
More from news
Approximately 24 fully matching, plus 72 partially matching documents found.
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene
Gilead’s subsidiary, Kite, has agreed a deal for a research collaboration with HiFiBiO Therapeutics, the Hong Kong-based company which is working on the discovery of therapeutic antibodies through single
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark has signed a marketing deal with Novartis in Europe, which means the big pharma company will set the
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Kite . Kite, a Gilead company, has appointed two new additions to its leadership team. ... Also joining Kite is Ken Takeshita, who has been appointed as global head of clinical development.
Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
Dr Riva joined the biopharmaceutical group in January 2017, and his previous role saw him take responsibility in expanding Gilead’s oncology programme with the recent acquisition of Kite Pharma. ... John McHutchinson, executive vice president, clinical
Dr Jian Irish becomes senior vice president of supply chain. California-based Kite Pharma has appointed Dr Jian Irish as senior vice president of supply chain. ... Tim Moore, executive vice president of technical operations at Kite Pharma, said: “Jian
He is currently chairman of Diageo, a consumer goods company, and a non-executive director of Chugai P harmaceuticals, Citigroup and Kite Pharma.
More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.
Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...